N-acetylaspartate reductions in the mediodorsal and anterior thalamus in men with schizophrenia verified by tissue volume corrected proton MRSI

OBJECTIVE Deficits in the mediodorsal and anterior nuclei of the thalamus may contribute to the psychopathological symptoms of schizophrenia. These thalamic nuclei have been found to be abnormal in schizophrenia and have close connections with other brain structures implicated in the disorder. We therefore examined schizophrenia-related alterations in brain metabolite levels specifically in the mediodorsal and anterior thalamic subregions. METHOD We used in vivo proton magnetic resonance spectroscopic imaging ((1)H MRSI) to measure N-acetylaspartate (NAA), choline-containing compounds (Cho), and creatine+phosphocreatine (Cr) in the mediodorsal and anterior thalamus in 22 male patients with schizophrenia and 22 male controls. Magnetic resonance imaging (MRI) tissue segmentation and thalamic volume mask techniques were performed to distinguish the thalamus, extrathalamic gray and white matter, and CSF within the spectroscopic voxels. RESULTS Compared to healthy subjects, patients with schizophrenia had significantly lower NAA in the mediodorsal and anterior thalamus bilaterally. No significant differences in Cho or Cr levels were seen. NAA was significantly higher in the left thalamus relative to the right in both groups. We found a strong negative correlation between left thalamic NAA and duration of illness, even after partialling out the effect of age. Tissue segmentation and thalamic volume mask techniques detected no group or lateralized differences in tissue type or CSF percentages, demonstrating that the metabolite reductions were not an artifact of spectroscopic voxel heterogeneity. CONCLUSIONS These findings suggest diminished function and/or structure in the mediodorsal and anterior thalamus in male patients with schizophrenia and support earlier research demonstrating schizophrenia-related abnormalities in the thalamus and its circuitry.

[1]  Dorothee P. Auer,et al.  Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation , 2001, Schizophrenia Research.

[2]  Ravi S. Menon,et al.  Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. , 2003, The American journal of psychiatry.

[3]  R. Coppola,et al.  Thalamic and Caudate Volumes in Monozygotic Twins Discordant for Schizophrenia , 2001, The Australian and New Zealand journal of psychiatry.

[4]  A W Toga,et al.  Brain abnormalities observed in childhood-onset schizophrenia: a review of the structural magnetic resonance imaging literature. , 2000, Mental retardation and developmental disabilities research reviews.

[5]  Koichi Mori,et al.  Proton magnetic resonance spectroscopy of the inferior frontal gyrus and thalamus and its relationship to verbal learning task performance in patients with schizophrenia: A preliminary report , 2002, Psychiatry and clinical neurosciences.

[6]  Peter Falkai,et al.  Volumes of association thalamic nuclei in schizophrenia: a postmortem study , 2003, Schizophrenia Research.

[7]  N Schuff,et al.  Reduced concentrations of thalamic N-acetylaspartate in male patients with schizophrenia. , 2000, The American journal of psychiatry.

[8]  B. Pakkenberg,et al.  Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. , 1990, Archives of general psychiatry.

[9]  Peter Stoeter,et al.  Altered effective connectivity during working memory performance in schizophrenia: a study with fMRI and structural equation modeling , 2003, NeuroImage.

[10]  D. Rothman,et al.  Neuronal and glial metabolite content of the epileptogenic human hippocampus , 2002, Annals of neurology.

[11]  J Hennig,et al.  Absence of N‐acetylaspartate in the human brain: Impact on neurospectroscopy? , 2001, Annals of neurology.

[12]  R Jayasundar Human brain: biochemical lateralization in normal subjects. , 2002, Neurology India.

[13]  R. Ledeen,et al.  Intraneuronal N‐acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin‐associated aspartoacylase , 2001, Journal of neurochemistry.

[14]  J. Newcomer,et al.  NMDA receptor hypofunction model of schizophrenia. , 1999, Journal of psychiatric research.

[15]  P. Barker,et al.  N‐Acetyl Aspartate—A Neuronal Marker? , 2001, Annals of neurology.

[16]  R S Kahn,et al.  Structural brain abnormalities in chronic schizophrenia at the extremes of the outcome spectrum. , 2001, The American journal of psychiatry.

[17]  Nancy C. Andreasen,et al.  Manual and Automated Measurement of the Whole Thalamus and Mediodorsal Nucleus Using Magnetic Resonance Imaging , 2002, NeuroImage.

[18]  Ron Kikinis,et al.  Volumetric Evaluation of the Thalamus in Schizophrenic Male Patients Using Magnetic Resonance Imaging , 1998, Biological Psychiatry.

[19]  R S Kahn,et al.  Partial volume decrease of the thalamus in relatives of patients with schizophrenia. , 1998, The American journal of psychiatry.

[20]  Cheuk Y. Tang,et al.  Abnormal glucose metabolism in the mediodorsal nucleus of the thalamus in schizophrenia. , 2004, The American journal of psychiatry.

[21]  V. Govindaraju,et al.  Automated spectral analysis III: Application to in Vivo proton MR Spectroscopy and spectroscopic imaging , 1998, Magnetic resonance in medicine.

[22]  T Sharma,et al.  Magnetic resonance imaging of the thalamus in first-episode psychosis. , 2001, The American journal of psychiatry.

[23]  K O Lim,et al.  In vivo spectroscopic quantification of the N‐acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: Effects of normal aging , 1999, Magnetic resonance in medicine.

[24]  M W Weiner,et al.  Spectroscopic imaging display and analysis. , 1992, Magnetic resonance imaging.

[25]  B. Cohen,et al.  Activation of midline thalamic nuclei by antipsychotic drugs , 1998, Psychopharmacology.

[26]  D R Medoff,et al.  Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. , 1996, The American journal of psychiatry.

[27]  K O Lim,et al.  Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. , 1998, Archives of general psychiatry.

[28]  S. Paradiso,et al.  Recalling word lists reveals "cognitive dysmetria" in schizophrenia: a positron emission tomography study. , 1999, The American journal of psychiatry.

[29]  David Bonekamp,et al.  Asymmetry and gender effect in functionally lateralized cortical regions: A proton MRS imaging study , 2004, Journal of magnetic resonance imaging : JMRI.

[30]  J. Clark,et al.  N-Acetyl Aspartate: A Marker for Neuronal Loss or Mitochondrial Dysfunction , 1998, Developmental Neuroscience.

[31]  J. Coyle,et al.  The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. , 2001, The American journal of psychiatry.

[32]  N. Schuff,et al.  Method to correlate 1H MRSI and 18FDG‐PET , 2000, Magnetic resonance in medicine.

[33]  Peter Bachert,et al.  A Fully Automated Method for Tissue Segmentation and CSF-Correction of Proton MRSI Metabolites Corroborates Abnormal Hippocampal NAA in Schizophrenia , 2002, NeuroImage.

[34]  H. Tost,et al.  Sensory information processing in neuroleptic-naive first-episode schizophrenic patients: a functional magnetic resonance imaging study. , 2002, Archives of general psychiatry.

[35]  David S Tuch,et al.  Automatic segmentation of thalamic nuclei from diffusion tensor magnetic resonance imaging , 2003, NeuroImage.

[36]  R. McCarley,et al.  MRI anatomy of schizophrenia , 1999, Biological Psychiatry.

[37]  M S Buchsbaum,et al.  PET and MRI of the thalamus in never-medicated patients with schizophrenia. , 1996, The American journal of psychiatry.

[38]  Hirohiko Kimura,et al.  Thalamic abnormalities in patients with schizophrenia revealed by proton magnetic resonance spectroscopy , 2000, Psychiatry Research: Neuroimaging.

[39]  D. Louis Collins,et al.  Design and construction of a realistic digital brain phantom , 1998, IEEE Transactions on Medical Imaging.

[40]  W. Reddick,et al.  More than meets the eye: significant regional heterogeneity in human cortical T1. , 2000, Magnetic resonance imaging.

[41]  Ravi S. Menon,et al.  Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. , 2002, The American journal of psychiatry.

[42]  B. Morris,et al.  Induction of differential patterns of local cerebral glucose metabolism and immediate-early genes by acute clozapine and haloperidol , 2002, Neuropharmacology.

[43]  A. Pfefferbaum,et al.  Effects of alcohol dependence comorbidity and antipsychotic medication on volumes of the thalamus and pons in schizophrenia. , 2003, The American journal of psychiatry.

[44]  B. Trapp,et al.  N‐acetylaspartate is an axon‐specific marker of mature white matter in vivo: A biochemical and immunohistochemical study on the rat optic nerve , 2002, Annals of neurology.

[45]  P. Teale,et al.  The thalamus and the schizophrenia phenotype: failure to replicate reduced volume , 1999, Biological Psychiatry.

[46]  Peter Herscovitch,et al.  Age, sex and laterality effects on cerebral glucose metabolism in healthy adults , 2002, Psychiatry Research: Neuroimaging.

[47]  L. Siever,et al.  Magnetic resonance imaging of the thalamic mediodorsal nucleus and pulvinar in schizophrenia and schizotypal personality disorder. , 2001, Archives of general psychiatry.

[48]  Paul J. Harrison,et al.  A postmortem study of the mediodorsal nucleus of the thalamus in schizophrenia , 2003, Schizophrenia Research.

[49]  Tetsuya Mori,et al.  Gender differences in cerebral glucose metabolism: a PET study , 2002, Journal of the Neurological Sciences.

[50]  D. Braus,et al.  Lower concentration of thalamic n-acetylaspartate in patients with schizophrenia: a replication study. , 2001, The American journal of psychiatry.

[51]  M S Buchsbaum,et al.  Correlational patterns of cerebral glucose metabolism in never-medicated schizophrenics. , 1996, Neuropsychobiology.

[52]  B. Pakkenberg,et al.  The volume of the mediodorsal thalamic nucleus in treated and untreated schizophrenics , 1992, Schizophrenia Research.

[53]  N. Andreasen,et al.  Effects of olanzapine on cerebellar functional connectivity in schizophrenia measured by fMRI during a simple motor task , 2001, Psychological Medicine.

[54]  S. Dollfus,et al.  Proton magnetic resonance spectroscopy (1H-MRS) of the thalamus in schizophrenia , 2000, European Psychiatry.

[55]  K. Bhakoo,et al.  In Vitro Expression of N‐Acetyl Aspartate by Oligodendrocytes , 2000, Journal of neurochemistry.

[56]  J. Coyle,et al.  N-Acetylaspartate in neuropsychiatric disorders , 1995, Progress in Neurobiology.

[57]  D J Healy,et al.  Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. , 2000, The American journal of psychiatry.

[58]  J. Lauriello,et al.  Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure , 2002, Schizophrenia Research.

[59]  P M Matthews,et al.  N‐acetylaspartate: Usefulness as an indicator of viable neuronal tissue , 2001, Annals of neurology.

[60]  John Lauriello,et al.  Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia , 2001, Psychiatry Research: Neuroimaging.

[61]  Alan C. Evans,et al.  MRI Simulation Based Evaluation and Classifications Methods , 1999, IEEE Trans. Medical Imaging.

[62]  D. German,et al.  Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia , 2000, Biological Psychiatry.

[63]  Norbert Schuff,et al.  Increased thalamic N-acetylaspartate in male patients with familial bipolar I disorder , 2001, Psychiatry Research: Neuroimaging.

[64]  C. Heimberg,et al.  Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect , 1998, Psychiatry Research: Neuroimaging.

[65]  Alessandro Bertolino,et al.  Regionally Specific Neuronal Pathology in Untreated Patients with Schizophrenia: A Proton Magnetic Resonance Spectroscopic Imaging Study , 1998, Biological Psychiatry.

[66]  G Tedeschi,et al.  Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. , 1996, The American journal of psychiatry.

[67]  M. Baslow,et al.  Evidence supporting a role for N-acetyl-l-aspartate as a molecular water pump in myelinated neurons in the central nervous system An analytical review , 2002, Neurochemistry International.

[68]  M Noble,et al.  Specific Expression of N‐Acetylaspartate in Neurons, Oligodendrocyte‐Type‐2 Astrocyte Progenitors, and Immature Oligodendrocytes In Vitro , 1992, Journal of neurochemistry.

[69]  Tommaso Scarabino,et al.  Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. , 2003, The American journal of psychiatry.

[70]  J. Sweeney,et al.  Thalamic volumes in patients with first-episode schizophrenia. , 2001, The American journal of psychiatry.

[71]  K. Blennow,et al.  Reduction of the synaptic protein rab3a in the thalamus and connecting brain regions in post-mortem schizophrenic brains , 2000, Journal of Neural Transmission.

[72]  William Byne,et al.  Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. , 2002, The American journal of psychiatry.

[73]  J Star-Lack,et al.  High spatial resolution 1H‐MRSI and segmented MRI of cortical gray matter and subcortical white matter in three regions of the human brain , 1999, Magnetic resonance in medicine.

[74]  E G Jones,et al.  Subnucleus-specific loss of neurons in medial thalamus of schizophrenics. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[75]  Arthur W. Toga,et al.  1H MRSI evidence of metabolic abnormalities in childhood-onset schizophrenia , 2004, NeuroImage.

[76]  J. Callicott,et al.  The Relationship between Dorsolateral Prefrontal Neuronal N-Acetylaspartate and Evoked Release of Striatal Dopamine in Schizophrenia , 2000, Neuropsychopharmacology.

[77]  Thomas Becker,et al.  MRI T2 relaxation times of brain regions in schizophrenic patients and control subjects , 1997, Psychiatry Research: Neuroimaging.

[78]  M S Buchsbaum,et al.  Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum. , 1999, The American journal of psychiatry.

[79]  Christian Gaser,et al.  Supporting evidence for the model of cognitive dysmetria in schizophrenia — a structural magnetic resonance imaging study using deformation-based morphometry , 2000, Schizophrenia Research.

[80]  Matcheri S Keshavan,et al.  Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings–part I , 2000, Biological Psychiatry.

[81]  James C. Ehrhardt,et al.  Visualization of Subthalamic Nuclei with Cortex Attenuated Inversion Recovery MR Imaging , 2000, NeuroImage.

[82]  R. Gur,et al.  Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. , 1998, The American journal of psychiatry.

[83]  Núria Bargalló,et al.  Sustained attention impairment correlates to gray matter decreases in first episode neuroleptic-naive schizophrenic patients , 2003, NeuroImage.

[84]  N. Andreasen,et al.  Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naïve patients , 1997, The Lancet.

[85]  Shi-Jiang Li,et al.  Differentiation of metabolic concentrations between gray matter and white matter of human brain by in vivo 1H magnetic resonance spectroscopy , 1998, Magnetic resonance in medicine.

[86]  Katya Rubia,et al.  An fMRI study of reduced left prefrontal activation in schizophrenia during normal inhibitory function , 2001, Schizophrenia Research.

[87]  George Fein,et al.  Reliability of tissue volumes and their spatial distribution for segmented magnetic resonance images , 2001, Psychiatry Research: Neuroimaging.